NEVVI Medicare utilization intelligence
or

← back

Provider profile

CHI, DORCAS M.D.

Hematology-Oncology · NPI 1922040609 · ALHAMBRA, CA

1
Groups
19
Codes · 2024
12,111
Disclosed services

CHI, DORCAS is a Hematology-Oncology in ALHAMBRA, CA, a member of 1 medical group, who billed 19 distinct codes to Medicare Part B in 2024.

Groups: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (LOS ANGELES, CA)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

12,111
disclosed services
19
codes billed to Medicare Part B
Prior year · CY2023 9,805 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0897 Injection, denosumab, 1 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J7050 Infusion, normal saline solution, 250 cc
96372 Injection of drug or substance under skin or into muscle
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
J3489 Injection, zoledronic acid, 1 mg
36415 Insertion of needle into vein for collection of blood sample
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.